US Stock Insider Trading | Vir Biotechnology Disclosed 10 Insider Transactions on February 26

K-LinePoet · 2026-03-24T12:05:12+00:00

February 26, 2026, Vir Biotechnology disclosed insider trading activity. Director SATO VICKI L purchased 424,000 shares on February 24, while multiple executives sold shares. The company focuses on developing innovative therapies for infectious diseases and cancer, leveraging its proprietary technology platform to optimize antibody development.

K-LinePoet

2026-03-24 12:05:12

Abstract generation in progress

On February 26, 2026, Vir Biotechnology (VIR) disclosed 10 insider transactions. Director SATO VICKI L purchased 42,400 shares on February 25, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 26, 2026	Executive	Eisner Mark	February 25, 2026	Sell	1,889	9.82	18,500
February 26, 2026	Executive	de Verneuil Vanina	February 24, 2026	Sell	3,117	9.53	29,700
February 26, 2026	Director	De Backer Marianne	February 24, 2026	Sell	14,800	9.53	140,700
February 26, 2026	Executive	Eisner Mark	February 24, 2026	Sell	1,616	9.53	15,400
February 26, 2026	Director	SATO VICKI L	February 24, 2026	Sell	42,200	9.75	411,300
February 26, 2026	Executive	O’Byrne Jason	February 24, 2026	Sell	1,634	9.53	15,600
February 26, 2026	Director	SATO VICKI L	February 24, 2026	Buy	42,400	1.49	62,900
February 26, 2026	Director	SATO VICKI L	February 24, 2026	Sell	200	10.26	2,052
February 26, 2026	Executive	Sabatini Brent	February 24, 2026	Sell	1,430	9.53	13,600
February 26, 2026	Executive	de Verneuil Vanina	February 25, 2026	Sell	13,700	9.82	134,500

[Company Profile]

Vir Biotechnology, Inc. was incorporated on April 7, 2016, under the laws of Delaware. As a clinical-stage biopharmaceutical company, VIR is dedicated to enhancing the immune system to develop innovative therapies for severe infectious diseases and cancer. The company’s approach focuses on addressing complex mechanisms that allow these threats to evade immune defenses. Vir’s clinical pipeline includes therapies targeting delta hepatitis virus and various solid tumors, with ongoing clinical projects and trials showing promise for setting new standards of care. The company leverages its proprietary platforms DAISY and PRO-XTEN to optimize antibody development. With an experienced leadership team in immunology, infectious diseases, and oncology, VIR is committed to transforming lives through its groundbreaking therapies.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes